AU2001257428A1 - Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation - Google Patents

Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation

Info

Publication number
AU2001257428A1
AU2001257428A1 AU2001257428A AU5742801A AU2001257428A1 AU 2001257428 A1 AU2001257428 A1 AU 2001257428A1 AU 2001257428 A AU2001257428 A AU 2001257428A AU 5742801 A AU5742801 A AU 5742801A AU 2001257428 A1 AU2001257428 A1 AU 2001257428A1
Authority
AU
Australia
Prior art keywords
regulation
affect
compounds
methods
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257428A
Inventor
Deborah Beach
Paul S. Eder
Anthony Giordano
Greg Johannes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Message Pharmaceuticals Inc
Original Assignee
Message Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Message Pharmaceuticals Inc filed Critical Message Pharmaceuticals Inc
Publication of AU2001257428A1 publication Critical patent/AU2001257428A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
AU2001257428A 2000-04-28 2001-04-30 Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation Abandoned AU2001257428A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56017400A 2000-04-28 2000-04-28
US09560174 2000-04-28
PCT/US2001/013864 WO2001084155A1 (en) 2000-04-28 2001-04-30 Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation

Publications (1)

Publication Number Publication Date
AU2001257428A1 true AU2001257428A1 (en) 2001-11-12

Family

ID=24236683

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257428A Abandoned AU2001257428A1 (en) 2000-04-28 2001-04-30 Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation

Country Status (3)

Country Link
US (3) US7078171B2 (en)
AU (1) AU2001257428A1 (en)
WO (1) WO2001084155A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598079B2 (en) * 1998-12-24 2009-10-06 Novation Pharmaceuticals, Inc. Assay for identifying compounds which affect stability of mRNA
EP1373528B1 (en) * 2001-03-09 2008-08-13 Gene Stream Pty Ltd. Novel expression vectors
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
CA2514184C (en) * 2003-01-21 2016-04-12 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
WO2005049868A1 (en) * 2003-11-17 2005-06-02 Pct Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating her2 expression
US20080220983A1 (en) * 2007-03-08 2008-09-11 Switchgear Genomics A California Corporation Functional arrays for high throughput characterization of regulatory elements in untranslated regions of genes
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
WO2015186129A1 (en) 2014-06-02 2015-12-10 Technion Research & Development Foundation Limited. Compositions and methods of selectively inhibiting irp1 and treating inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444149A (en) 1992-05-11 1995-08-22 Duke University Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation
AU6497694A (en) 1993-04-02 1994-10-24 Ribogene, Inc. Method for selective inactivation of viral replication
US5641675A (en) * 1994-10-07 1997-06-24 University Of Massachusetts Medical Center Cis-acting sequences for intracellular localization of RNA
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5859227A (en) 1996-07-31 1999-01-12 Bearsden Bio, Inc. RNA sequences which interact with RNA-binding proteins
US6107029A (en) 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
WO1998012313A1 (en) * 1996-09-20 1998-03-26 Suntory Limited Method for screening compounds regulating the expression of human-inducible nitric oxide synthase
WO1998042854A1 (en) 1997-03-27 1998-10-01 The Board Of Trustees Of The Leland Stanford Junior University Functional genomic screen for rna regulatory sequences and interacting molecules
JP2002504820A (en) 1997-06-04 2002-02-12 スミスクライン・ビーチャム・コーポレイション Rapid cloning of full-length cDNA
US5985575A (en) * 1998-05-20 1999-11-16 Wisconsin Alumni Research Foundation Tethered function assay for protein function
US6083727A (en) 1999-06-30 2000-07-04 Incyte Pharmaceuticals Inc. Methods and compositions for producing 5' enriched cDNA libraries

Also Published As

Publication number Publication date
US7078171B2 (en) 2006-07-18
US20070154904A1 (en) 2007-07-05
US20110086105A1 (en) 2011-04-14
US20040091866A1 (en) 2004-05-13
WO2001084155A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2001235479A1 (en) Container for nucleic acid analysis
AU2001243489A1 (en) Rapid entry system for the placement of orders via the internet
AU2002332940A1 (en) Device for analyzing nucleic acid
AU2001264402A1 (en) Methods for identifying crystallization conditions for biomolecules
AU2001257428A1 (en) Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation
AU2002316863A1 (en) Method for the preferential nucleic acid amplification of selected nucleic acid regions
AU2001237546A1 (en) Methods for characterizing polymorphisms
AU2002358273A1 (en) Nucleic acid-associated proteins
AU3433301A (en) Dehiscence gene and methods for regulating dehiscence
AU2001268040A1 (en) Methods and compounds for inhibiting mrp1
AU2001252390A1 (en) Nucleic acid immunization
AU2002359333A1 (en) Nucleic acid-associated proteins
AU2000259734A1 (en) Method for identifying compounds with anti-herpes activity
AU2001265759A1 (en) Method for the highly parallel analysis of polymorphisms
AUPQ521300A0 (en) Improved kit handling system
AU2001260313A1 (en) Compositions and methods for nucleic acid analyses
AU2001253386A1 (en) Haplotypes of the impdh2 gene
AU4444201A (en) Support for trotline or fish stringers
AU2002364883A1 (en) Means for identifying neisseiria menengitidis specific genes
AU2001295689A1 (en) Compositions and methods for regulating the nervous system
AU2002256993A1 (en) Nucleic acid-associated proteins
AU2002232822A1 (en) Nucleic acid-associated proteins
AU5417700A (en) Method for identifying novel transcriptional regulatory proteins
AU4107500A (en) Nucleic acid combination
AU2001286744A1 (en) Compounds and methods for inhibiting neuronal cell death